ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study (2022)
Sen, Parikshit; Lilleker, James B; Agarwal, Vishwesh; Kardes, Sinan; Milchert, Marcin; Gheita, Tamer; Salim, Babur; Velikova, Tsvetelina; Gracia-Ramos, Abraham Edgar; Shinjo, Samuel Katsuyuki
Source: Indian journal of rheumatology. Unidade: FM
Subjects: DOENÇAS AUTOIMUNES, COVID-19, VACINAS VIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SEN, Parikshit et al. Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian journal of rheumatology. Mumbai: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.4103/injr.injr_221_21. Acesso em: 23 abr. 2024. , 2022
APA
Sen, P., Lilleker, J. B., Agarwal, V., Kardes, S., Milchert, M., Gheita, T., et al. (2022). Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian journal of rheumatology. Mumbai: Faculdade de Medicina, Universidade de São Paulo. doi:10.4103/injr.injr_221_21
NLM
Sen P, Lilleker JB, Agarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Shinjo SK. Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study [Internet]. Indian journal of rheumatology. 2022 ; 17( 2): 188-191.[citado 2024 abr. 23 ] Available from: https://doi.org/10.4103/injr.injr_221_21
Vancouver
Sen P, Lilleker JB, Agarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Shinjo SK. Vaccine hesitancy in patients with autoimmune diseases. [Carta]: data from the coronavirus disease-2019 vaccination in autoimmune diseases study [Internet]. Indian journal of rheumatology. 2022 ; 17( 2): 188-191.[citado 2024 abr. 23 ] Available from: https://doi.org/10.4103/injr.injr_221_21
Artigo de periodico
Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) (2019)
Causland, Finnian R. Mc; Claggett, Brian; Burdmann, Emmanuel de Almeida; Chertow, Glenn M; Cooper, Mark E; Eckardt, Kai-Uwe; Ivanovich, Peter; Levey, Andrew S; Lewis, Eldrin F; Mcgill, Janet B
Source: American journal of kidney diseases. Unidade: FM
Subjects: ANEMIA, ERITROPOIETINA, HEMODIÁLISE, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAUSLAND, Finnian R. Mc et al. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). American journal of kidney diseases, v. 73, n. 3, p. 309-315, 2019Tradução . . Disponível em: https://doi.org/10.1053/j.ajkd.2018.10.006. Acesso em: 23 abr. 2024.
APA
Causland, F. R. M., Claggett, B., Burdmann, E. de A., Chertow, G. M., Cooper, M. E., Eckardt, K. -U., et al. (2019). Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT). American journal of kidney diseases, 73( 3), 309-315. doi:10.1053/j.ajkd.2018.10.006
NLM
Causland FRM, Claggett B, Burdmann E de A, Chertow GM, Cooper ME, Eckardt K-U, Ivanovich P, Levey AS, Lewis EF, Mcgill JB. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) [Internet]. American journal of kidney diseases. 2019 ; 73( 3): 309-315.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1053/j.ajkd.2018.10.006
Vancouver
Causland FRM, Claggett B, Burdmann E de A, Chertow GM, Cooper ME, Eckardt K-U, Ivanovich P, Levey AS, Lewis EF, Mcgill JB. Treatment of anemia with darbepoetin prior to dialysis initiation and clinical outcomes: analyses from the trial to reduce cardiovascular events with aranesp therapy (TREAT) [Internet]. American journal of kidney diseases. 2019 ; 73( 3): 309-315.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1053/j.ajkd.2018.10.006
Artigo de periodico
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) (2018)
Vallejo-vaz, Antonio J; Santos Filho, Raul Dias dos
Source: Atherosclerosis. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, COOPERAÇÃO INTERNACIONAL, MÉTODOS EPIDEMIOLÓGICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VALLEJO-VAZ, Antonio J e SANTOS FILHO, Raul Dias dos. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, v. 277, p. 234-255, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.atherosclerosis.2018.08.051. Acesso em: 23 abr. 2024.
APA
Vallejo-vaz, A. J., & Santos Filho, R. D. dos. (2018). Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 277, 234-255. doi:10.1016/j.atherosclerosis.2018.08.051
NLM
Vallejo-vaz AJ, Santos Filho RD dos. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) [Internet]. Atherosclerosis. 2018 ; 277 234-255.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2018.08.051
Vancouver
Vallejo-vaz AJ, Santos Filho RD dos. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) [Internet]. Atherosclerosis. 2018 ; 277 234-255.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2018.08.051
Artigo de periodico
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease (2019)
Charytan, David M; Solomon, Scott D; Ivanovich, Peter; Remuzzi, Giuseppe; Cooper, Mark E; Mcgill, Janet B; Parving, Hans-Henrik; Parfrey, Patrick; Singh, Ajay K; Burdmann, Emmanuel de Almeida
Source: Diabetes obesity & metabolism. Unidade: FM
Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, INSUFICIÊNCIA RENAL CRÔNICA, METFORMINA, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHARYTAN, David M et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes obesity & metabolism, v. 21, n. 5, p. 1199-1208, 2019Tradução . . Disponível em: https://doi.org/10.1111/dom.13642. Acesso em: 23 abr. 2024.
APA
Charytan, D. M., Solomon, S. D., Ivanovich, P., Remuzzi, G., Cooper, M. E., Mcgill, J. B., et al. (2019). Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes obesity & metabolism, 21( 5), 1199-1208. doi:10.1111/dom.13642
NLM
Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, Mcgill JB, Parving H-H, Parfrey P, Singh AK, Burdmann E de A. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease [Internet]. Diabetes obesity & metabolism. 2019 ; 21( 5): 1199-1208.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1111/dom.13642
Vancouver
Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, Mcgill JB, Parving H-H, Parfrey P, Singh AK, Burdmann E de A. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease [Internet]. Diabetes obesity & metabolism. 2019 ; 21( 5): 1199-1208.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1111/dom.13642
Artigo de periodico-carta/editorial
Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary (2017)
Santos Filho, Raul Dias dos
Source: Current opinion in lipidology. Unidade: FM
Subjects: GENÉTICA MÉDICA, EPIDEMIOLOGIA, BIOLOGIA CELULAR, ESTUDOS RANDOMIZADOS, COLESTEROL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos. Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary. Current opinion in lipidology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1097/MOL.0000000000000460. Acesso em: 23 abr. 2024. , 2017
APA
Santos Filho, R. D. dos. (2017). Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary. Current opinion in lipidology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. doi:10.1097/MOL.0000000000000460
NLM
Santos Filho RD dos. Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary [Internet]. Current opinion in lipidology. 2017 ; 28( 6): 522-523.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1097/MOL.0000000000000460
Vancouver
Santos Filho RD dos. Genetics and molecular biology controversies on Mendelian randomization and proprotein convertase subtilisin-kexin type 9 inhibitor clinical trials [Editorial]: more data still necessary [Internet]. Current opinion in lipidology. 2017 ; 28( 6): 522-523.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1097/MOL.0000000000000460
Artigo de periodico
Familial hypercholesterolaemia (2017)
Defesche, Joep C.; Gidding, Samuel S.; Harada-Shiba, Mariko; Santos Filho, Raul Dias dos; Wierzbicki, Anthony S.
Source: Nature reviews disease primers. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, COLESTEROL, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DEFESCHE, Joep C. et al. Familial hypercholesterolaemia. Nature reviews disease primers, v. 3, 2017Tradução . . Disponível em: https://doi.org/10.1038/nrdp.2017.93. Acesso em: 23 abr. 2024.
APA
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Santos Filho, R. D. dos, & Wierzbicki, A. S. (2017). Familial hypercholesterolaemia. Nature reviews disease primers, 3. doi:10.1038/nrdp.2017.93
NLM
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 abr. 23 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Vancouver
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 abr. 23 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Artigo de periodico
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD (2017)
Charytan, David M.; Burdmann, Emmanuel de Almeida
Source: American journal of kidney diseases. Unidade: FM
Subjects: FALÊNCIA RENAL CRÔNICA, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHARYTAN, David M. e BURDMANN, Emmanuel de Almeida. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, v. 70, n. 4, p. 522-531, 2017Tradução . . Disponível em: http://observatorio.fm.usp.br/handle/OPI/21785. Acesso em: 23 abr. 2024.
APA
Charytan, D. M., & Burdmann, E. de A. (2017). ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, 70( 4), 522-531. doi:10.1053/j.ajkd.2017.04.018
NLM
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 abr. 23 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
Vancouver
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 abr. 23 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
Artigo de periodico
Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions (2018)
Albergaria, Ben-Hur; Chalem, Monique; Clark, Patricia; Messina, Osvaldo Daniel; Pereira, Rosa Maria Rodrigues; Vidal, Luis F.
Source: Archives of osteoporosis. Unidade: FM
Subjects: PRÁTICA CLÍNICA, OSTEOPOROSE, MENOPAUSA, PREVALÊNCIA, MULHERES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALBERGARIA, Ben-Hur et al. Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions. Archives of osteoporosis, v. 13, n. 1, 2018Tradução . . Disponível em: https://doi.org/10.1007/s11657-018-0505-x. Acesso em: 23 abr. 2024.
APA
Albergaria, B. -H., Chalem, M., Clark, P., Messina, O. D., Pereira, R. M. R., & Vidal, L. F. (2018). Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions. Archives of osteoporosis, 13( 1). doi:10.1007/s11657-018-0505-x
NLM
Albergaria B-H, Chalem M, Clark P, Messina OD, Pereira RMR, Vidal LF. Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions [Internet]. Archives of osteoporosis. 2018 ; 13( 1):[citado 2024 abr. 23 ] Available from: https://doi.org/10.1007/s11657-018-0505-x
Vancouver
Albergaria B-H, Chalem M, Clark P, Messina OD, Pereira RMR, Vidal LF. Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions [Internet]. Archives of osteoporosis. 2018 ; 13( 1):[citado 2024 abr. 23 ] Available from: https://doi.org/10.1007/s11657-018-0505-x
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 23 abr. 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
Everett, Brendan M.; Nicolau, Jose C.; DONATH, Marc Y.; PRADHAN, Aruna D.; THUREN, Tom; PAIS, Prem; GLYNN, Robert J; LIBBY, Peter; RIDKER, Paul M.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 23 abr. 2024.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Artigo de periodico
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract (2018)
Mach, Francois; Santos, Raul D
Source: European heart journal. Unidade: FM
Subjects: INSUFICIÊNCIA RENAL CRÔNICA, MORTALIDADE, DIABETES MELLITUS, ESTUDOS RANDOMIZADOS, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACH, Francois e SANTOS, Raul D. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European heart journal, v. 39, n. 27, p. 2526-+, 2018Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehy182. Acesso em: 23 abr. 2024.
APA
Mach, F., & Santos, R. D. (2018). Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European heart journal, 39( 27), 2526-+. doi:10.1093/eurheartj/ehy182
NLM
Mach F, Santos RD. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract [Internet]. European heart journal. 2018 ; 39( 27): 2526-+.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1093/eurheartj/ehy182
Vancouver
Mach F, Santos RD. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract [Internet]. European heart journal. 2018 ; 39( 27): 2526-+.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1093/eurheartj/ehy182

USP Schools

ReP

Filtros

Authors

Subjects

Source title

Funding Agencies